## ORBIT TECHNOLOGIES LTD.

## CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

## AS OF SEPTEMBER 30, 2022

## U.S. DOLLARS IN THOUSANDS

## **UNAUDITED**

## **INDEX**

	Page
Auditors' Letter	2
Consolidated Balance Sheets	3 - 4
Consolidated Statements of Income	5
Consolidated Statements of Comprehensive Income	6
Consolidated Statements of Changes in Equity	7 – 9
Consolidated Statements of Cash Flows	10 - 11
Note to Consolidated financial Statements	12

\_\_\_\_\_



Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A, Fax: +972-3-5622555 Tel-Aviv 6492102, Israel

Tel: +972-3-6232525 ev.com

To:

Orbit Technologies Ltd.

We have reviewed the financial information of Orbit Technologies Ltd. and its subsidiaries ("the Group"), which comprises the condensed consolidated balance sheet as of September 30, 2022 and 2021 and the related condensed consolidated statements of income, comprehensive income, changes in equity and cash flows for the nine and three months periods then ended in accordance with Review Standard 1 of the Institute of Certified Public Accountants in Israel.

Based on our review, in our review report dated November 21, 2022 we stated that nothing came to our attention that caused us to believe that the abovementioned interim financial information was not prepared, in all material respects, in accordance with IAS 34.

The accompanying financial information, which is derived from the abovementioned financial information, is condensed financial information and does not include disclosures required by IAS 34. If the omitted disclosures were included in the accompanying financial information, they might influence the user's conclusions about the consolidated financial position, results of operations and cash flows of the Company and subsidiaries. Accordingly, the accompanying financial information is not designed for those who are not informed about such matters.

Tel-Aviv, Israel November 21, 2022 **KOST FORER GABBAY & KASIERER** A Member of Ernst & Young Global

# CONSOLIDATED BALANCE SHEETS

	Septemb	er 30,	December 31,
	2022	2021	2021
	Unaud	lited	Audited
	U.S.	dollars in tho	usands
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	20,349	25,638	29,885
Accounts receivable	10,944	10,980	10,708
Amounts due for construction contracts	14,762	7,004	7,054
Other accounts receivable	1,659	1,241	1,500
Inventories	8,548	6,653	5,684
	56,262	51,516	54,831
NON-CURRENT ASSETS:			
Other assets	10	10	10
Fixed assets	15,278	7,934	14,607
Intangible assets	11,045	5,690	6,269
Goodwill	699	-	-
Deferred taxes	75	668	1,191
	27,107	14,302	22,077
	83,369	65,818	76,908

	Septemb	oer 30,	December 31,	
	2022	2021	2021	
	Unaud	lited	Audited	
	U.S.	dollars in tho	usands	
LIABILITIES AND EQUITY	-			
CURRENT LIABILITIES:				
Trade payables	9,528	6,645	7,323	
Income taxes payable	198	27	-	
Other accounts payable	12,945	14,204	14,931	
	22,671	20,876	22,254	
NON-CURRENT LIABILITIES:				
Liability for Government grants	556	536	516	
Employee benefit liability	330	328	346	
Lease payments liability	7,661	3,205	9,551	
Warranty liability	742	694	708	
Contingent liability related to acquisition	762	-	-	
Deferred taxes	393	9		
	10,444	4,772	11,121	
EQUITY:				
Share capital	6,515	6,483	6,493	
Paid-in capital	21,252	21,013	21,039	
Warrants	1,761	1,761	1,761	
Retained earnings	19,973	10,543	13,696	
Reserve for share-based payment	1,716	953	1,118	
Foreign currency translation adjustments	(747)	(370)	(358)	
Reserve for defined benefit plans	651	654	651	
Treasury shares	(867)	(867)	(867)	
Total equity	50,254	40,170	43,533	
	83,369	65,818	76,908	

November 21, 2022			
Date of approval of the	Yitzchak Gat	D. Eshchar	R. Wirth
financial statements	Chairman of the Board	CEO	CFO

# CONSOLIDATED STATEMENTS OF INCOME

	Nine months ended September 30,		Three mon Septem	Year ended December 31,	
	2022	2021	2022	2021	2021
		Unau	ıdited		Audited
	U.S.	dollars in t	housands (ex	cept per sh	nare data)
Revenues from sales and contracts					
performed	42,570	38,887	16,017	14,036	54,789
Cost of sales and contracts performed	27,007	24,894	9,917	8,550	34,559
Gross profit	15,563	13,993	6,100	5,486	20,230
Research and development costs, net	2,533	2,646	935	933	3,672
Selling and marketing expenses	4,017	4,032	1,494	1,309	5,713
General and administrative expenses	3,018	2,773	1,041	839	3,694
Operating income before other expenses	5,995	4,542	2,630	2,405	7,151
Other expenses (income)	231	39		8	(16)
Operating income after other expenses	5,764	4,503	2,630	2,397	7,167
Finance income	2,185	19	416	-	24
Finance expenses	256	363	98	123	548
Income before taxes on income	7,693	4,159	2,948	2,274	6,643
tax expense (Income)	1,416	35	552	18	(634)
Net profit	6,277	4,124	2,396	2,256	7,277
Net profit per share attributable to equity holders of the Company (in U.S. dollars):					
Basic profit per share	0.337	0.222	0.129	0.122	0.391
Diluted profit per share	0.282	0.186	0.107	0.101	0.326

# CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Nine months ended September 30,		Three mon Septem	Year ended December 31,					
	2022	2021	2022	2021	2021				
		Unau	ıdited		Audited				
		U.S. dollars in thousands							
Net profit	6,277	4,124	2,396	2,256	7,277				
Other comprehensive income (net of tax effect):									
Actuarial loss from defined benefit plans Foreign currency translation adjustments	-	-	-	-	(3)				
of foreign operation	(389)	(36)	(158)	(65)	(24)				
Total other comprehensive loss	(389)	(36)	(158)	(65)	(27)				
Total comprehensive income	5,888	2,786	2,238	2,191	7,250				

	Equity attributable to equity holders of the Company									
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Treasury shares	Total equity	
	-					idited in thousands				
	-				U.S. donars	in thousands				
Balance at January 1, 2022 (audited)	6,493	21,039	1,761	13,696	1,118	(358)	651	(867)	43,533	
Net Income Other comprehensive loss		<u>-</u>	<u>-</u>	6,277	<u>-</u>	(389)	<u>-</u>		6,277 (389)	
Total comprehensive income (loss) Exercise of warrants into shares Cost of share based-payment	22	213	- - -	6,277 - -	(72) 670	(389)	- - -	- - -	5,888 163 670	
Balance at September 30, 2022	6,515	21,252	1,761	19,973	1,716	(747)	651	(867)	50,254	
				Equity attr	ibutable to equi	ty holders of the Com	pany			
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Treasury shares	Total equity	
					Ullat	iuiteu				

	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Treasury shares	Total equity			
		Unaudited U.S. dollars in thousands										
Balance at January 1, 2021 (audited)	6,458	20,788	1,761	6,419	821	(334)	654	(867)	35,700			
Net profit Other comprehensive loss				4,124		(36)			4,124 (36)			
Total comprehensive income (loss) Exercise of warrants into shares Forfeiture of Options Cost of share based-payment	25	225	- - - -	4,124 - - -	(129) (15) 276	(36)	- - - -	- - - -	4,088 121 (15) 276			
Balance at September 30, 2021	6,483	21,013	1,761	10,543	953	(370)	654	(867)	40,170			

(867)

212

50,254

Cost of share based-payment

Balance at September 30, 2022

		Equity attributable to equity holders of the Company										
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Treasury shares	Total equity			
		Unaudited										
		U.S. dollars in thousands										
Balance at July 1, 2022	6,501	21,089	1,761	17,577	1,526	(589)	651	(867)	47,649			
Net Income	-	_	-	2,396	_	-	-	-	2,396			
Other comprehensive loss						(158)			(158)			
Total comprehensive income (loss)	-	_	-	2,396	_	(158)	-	_	2,238			
Exercise of warrants into shares	14	163	-	-	(22)	-	-	-	155			

19,673

#### Equity attributable to equity holders of the Company

(747)

651

212

1,716

	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Treasury shares	Total equity		
		Unaudited U.S. dollars in thousands									
Balance at July 1, 2021	6,467	20,991	1,761	8,287	848	(305)	654	(867)	37,836		
Net profit Other comprehensive income (loss)		<u>-</u>		2,256	-	(65)	<u> </u>	<u>-</u>	2,256 (65)		
Total comprehensive loss (loss) Exercise of options into shares Forfeiture of Options Cost of share based-payment	16 - -	22	- - -	2,256	(15) (5) 125	(65) - - -	- - - -	- - - -	2,191 23 (5) 125		
Balance at September 30, 2021	6,483	21,013	1,761	10,543	953	(370)	654	(867)	40,170		

The accompanying note is an integral part of the interim consolidated financial statements.

6,515

21,252

1,761

	Equity attributable to equity holders of the Company										
	Share capital	Paid-in capital	Warrants	Retained earnings	Reserve for share-based payment	Foreign currency translation adjustments	Proceeds from conversion option	Reserve for defined benefit plans	Treasury shares	Total equity	
	U.S. dollars in thousands										
					A	udited					
Balance at December 31, 2020	6,458	20,788	1,761	6,419	821	(334)	-	654	(867)	35,700	
Net income Other comprehensive loss	_ 		- 	7,277	-	(24)	<u>-</u>	(3)	- -	7,277 (27)	
Total comprehensive Income (loss) Exercise of warrants into shares by controlling	-	-	-	7,277	-	(24)	-	(3)	-	7.250	
shareholder	35	251	-	-	(156)	_	_	_	-	130	
Forfeiture of options	-	-	-	-	(15)	-	-	-	-	(15)	
Cost of share based-payment			. <u> </u>	-	468					468	
Balance at December 31, 2021	6,493	21,039	1,761	13,696	1,118	(358)		651	(867)	43,533	

## CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended September 30,		Three mon Septemb		Year ended December 31,	
	2022	2021	2022	2021	2021	
		Unau	dited		Audited	
		U.S	. dollars in th	nousands		
Cash flows from operating activities:						
Net income	6,277	4,124	2,396	2,256	7,277	
Adjustments to reconcile loss to net cash provided by operating activities:						
Adjustments to the profit or loss items:						
Depreciation and amortization Capital Gain from sale of fixed assets	2,494	1,864	930	634	2,591 1	
Cost of share-based payment	670	261	212	109	453	
Tax expense	1,416	35	552	18	(634)	
Interest expenses, net	135	249	15	89	371	
Change in employee benefit liability, net	(117)	_	(16)	5	16	
Adjustment to current accounts with	( )		` ′			
foreign operation	(116)	51	8	11	42	
	4,482	2,460	1,701	866	2,840	
Changes in operating asset and liability items:						
Decrease (increase) in trade receivables Decrease (increase) in amounts due for	877	550	(2,078)	2,031	822	
construction contracts Decrease (increase) in other accounts	(7,708)	(1,880)	(3,856)	1,156	(1,930)	
receivable	(515)	(435)	172	154	(458)	
Decrease (increase) in inventories	(2,143)	(933)	(916)	27	(239)	
Increase (decrease) in trade payables Increase (decrease) in other accounts	933	444	586	(474)	1,001	
payable	(4,780)	317	336	1,590	1,239	
	(13,336)	(1,937)	(6,170)	4,484	435	
Cash paid and received during the period for:						
Interest paid	(248)	(268)	(90)	(196)	(369)	
Interest received	113	19	77	1	24	
Taxes paid	(84)	(36)	(26)	(5)	(172)	
	(219)	(285)	(39)	(200)	(544)	
Net cash provided by (used in) operating activities	(2,796)	4,362	(2,112)	7,406	10,008	

# CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2022	2021	2022	2021	2021
		Unaudited			Audited
		U.S. dollars in thousands			
Cash flows from investing activities:					
Purchase of fixed assets Net cash used to activity acquisition Capitalization of research and development	(981) (1,352)	(641)	(249)	(281)	(931)
costs	(3,421)	(463)	(1,116)	(121)	(1,146)
Net Used in investing activities	(5,754)	(1,104)	(1,365)	(402)	(2,077)
Cash flows from financing activities: Payments of lease liability Payments for Government grants	(1,261) (4)	(1,245)	(435) (4)	(439)	(1,690)
Exercise of warrants into shares	163	121	155	33	129
Exercise of warrants into shares	103	121			12)
Net cash used in financing activities	(1,102)	(1,124)	(284)	(406)	(1,561)
Translation differences on balances of cash and cash equivalents	116	(51)	(8)_	(12)	(40)
Increase (decrease) in cash and cash equivalents	(9,536)	2,083	(3,769)	6,586	6,330
Cash and cash equivalents at the beginning of the period	29,885	23,555	24,118	19,052	23,555
Cash and cash equivalents at the end of the period	20,349	25,638	20,349	25,638	29,885
Significant non-cash transaction:					
Purchase of fixed assets on suppliers credit	1,200	102	1,097	102	222
Recognition of the right of use against a lease liability	490	458	96	218	7,088

### **NOTE 1:- GENERAL**

These financial statements have been prepared in a condensed format as of September 30, 2022 and for the six and three months then ended ("interim financial statements"). These financial statements should be read in conjunction with the Company's annual financial statements as of December 31, 2021 and for the year then ended and accompanying notes ("annual financial statements").

\_ \_ \_ \_ \_ \_ \_ \_ \_ \_